Adial Pharmaceuticals Regains Compliance with Nasdaq Stockholders’ Equity Listing Requirement

Contact: Crescendo Communications, LLC David Waldman / Alexandra Schilt Tel: 212-671-1020 GLEN ALLEN, Va., July 16, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it received notice from Nasdaq on July 14, 2025 that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1), which req ...